Q3 2025 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-283112
$610.9M
Reported value
40
Positions
2025-09-30
Period end
The Brief · MPM BioImpact LLC · Q3 2025
AI · grounded in 13F
MPM BioImpact LLC closed its position in Guardant Health Inc GH, reducing its exposure by $23.04M. The fund established a new position in Syndax Pharmaceuticals Inc SNDX worth $21.16M. Other notable activity includes new stakes in Liquidia Corp LQDA and Palvella Therapeutics Inc PVLA, alongside a 200% increase in shares of Soleno Therapeutics Inc SLNO.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 558868105 | MDGL | Madrigal Pharmaceuticals Inc | $46.1M | 7.54% | 100,415 | Common | SOLE |
| 230031106 | CGEM | Cullinan Therapeutics, Inc. | $45.4M | 7.42% | 7,648,268 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $33.1M | 5.42% | 760,022 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $31.2M | 5.10% | 3,406,955 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $27.9M | 4.57% | 1,720,741 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $26.9M | 4.41% | 438,477 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $25.3M | 4.13% | 745,060 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals Inc | $21.2M | 3.46% | 1,375,674 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $20.8M | 3.40% | 1,729,378 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $20.3M | 3.32% | 341,496 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $20.2M | 3.31% | 503,398 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics Inc | $18.6M | 3.04% | 789,698 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $18.3M | 3.00% | 1,446,361 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $17.8M | 2.91% | 5,075,970 | Common | SOLE |
| G01767105 | ALKS | Alkermes Plc | $16.5M | 2.70% | 549,262 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc. | $16.4M | 2.68% | 563,075 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $15.9M | 2.61% | 98,924 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $15.0M | 2.46% | 614,282 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $14.7M | 2.41% | 315,722 | Common | SOLE |
| 21077P108 | CNTX | Context Therapeutics Inc | $14.2M | 2.33% | 14,705,882 | Common | SOLE |
| 803607100 | SRPT | Sarepta Therapeutics Inc | $13.5M | 2.21% | 700,000 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals Inc | $13.1M | 2.14% | 1,303,399 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $12.7M | 2.08% | 3,903,381 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $11.9M | 1.95% | 2,282,680 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $11.9M | 1.95% | 395,700 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences PTE LTD | $11.0M | 1.80% | 1,505,262 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S A | $10.5M | 1.73% | 1,054,504 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $10.1M | 1.66% | 150,000 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $10.1M | 1.65% | 1,634,569 | Common | SOLE |
| 00972D105 | AKBA | Akebia Therapeutics Inc | $7.9M | 1.29% | 2,889,125 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $4.7M | 0.78% | 2,408,810 | Common | SOLE |
| 53635D202 | LQDA | Liquidia Corp | $4.5M | 0.74% | 200,000 | Common | SOLE |
| 697947109 | PVLA | Palvella Therapeutics Inc | $4.2M | 0.69% | 67,423 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics Inc | $4.2M | 0.68% | 555,187 | Common | SOLE |
| 816212302 | RNAC | Cartesian Therapeutics Inc | $3.9M | 0.64% | 380,000 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc | $3.6M | 0.59% | 530,299 | Common | SOLE |
| M96088105 | URGN | Urogen Pharma Ltd | $2.7M | 0.44% | 135,000 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $2.1M | 0.35% | 71,807 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $1.4M | 0.24% | 819,924 | Common | SOLE |
| 045396207 | ASMB | Assembly Biosciences Inc | $1.0M | 0.17% | 39,665 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.